A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Incyte Corporation
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group
Boehringer Ingelheim
H. Lee Moffitt Cancer Center and Research Institute
Goethe University
Henan Cancer Hospital
Dana-Farber Cancer Institute
Baylor College of Medicine
University of California, San Diego
University of Washington
Institut Bergonié
University of Miami
The Cleveland Clinic
International Extranodal Lymphoma Study Group (IELSG)
Dana-Farber Cancer Institute
Institut Bergonié
Amgen
Janssen Research & Development, LLC
Thomas Jefferson University
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University College, London
The University of Texas Health Science Center, Houston
National Cancer Institute (NCI)
Technische Universität Dresden
M.D. Anderson Cancer Center
International Extranodal Lymphoma Study Group (IELSG)
Universitätsklinikum Hamburg-Eppendorf
RemeGen Co., Ltd.
SWOG Cancer Research Network
Grupo Espanol de Investigacion en Sarcomas
M.D. Anderson Cancer Center
Children's Oncology Group
Amgen
Italian Sarcoma Group
Children's Oncology Group
Sun Yat-sen University
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Queen Mary University of London
European Organisation for Research and Treatment of Cancer - EORTC
Gustave Roussy, Cancer Campus, Grand Paris
Roswell Park Cancer Institute
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Dartmouth-Hitchcock Medical Center